Genetic architecture of plasma Alzheimer disease biomarkers

• Published in: Human molecular genetics 2023-07, Vol.32 (15), p.2532-2543
• Main Authors: Bradley, Joseph, Gorijala, Priyanka, Schindler, Suzanne E, Sung, Yun J, Ances, Beau, Fernandez, Maria V, Cruchaga, Carlos
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - genetics; Amyloid beta-Peptides - genetics; Association Studies; Biomarkers; Genome-Wide Association Study; Humans; Peptide Fragments - genetics; tau Proteins - genetics
• ISSN: 0964-6906; 1460-2083
• DOI: 10.1093/hmg/ddad087

Abstract Genome-wide association studies (GWAS) of cerebrospinal fluid (CSF) Alzheimer’s Disease (AD) biomarker levels have identified novel genes implicated in disease risk, onset and progression. However, lumbar punctures have limited availability and may be perceived as invasive. Blood collection is readily available and well accepted, but it is not clear whether plasma biomarkers will be informative for genetic studies. Here we perform genetic analyses on concentrations of plasma amyloid-β peptides Aβ40 (n = 1,467) and Aβ42 (n = 1,484), Aβ42/40 (n = 1467) total tau (n = 504), tau phosphorylated (p-tau181; n = 1079) and neurofilament light (NfL; n = 2,058). GWAS and gene-based analysis was used to identify single variant and genes associated with plasma levels. Finally, polygenic risk score and summary statistics were used to investigate overlapping genetic architecture between plasma biomarkers, CSF biomarkers and AD risk. We found a total of six genome-wide significant signals. APOE was associated with plasma Aβ42, Aβ42/40, tau, p-tau181 and NfL. We proposed 10 candidate functional genes on the basis of 12 single nucleotide polymorphism-biomarker pairs and brain differential gene expression analysis. We found a significant genetic overlap between CSF and plasma biomarkers. We also demonstrate that it is possible to improve the specificity and sensitivity of these biomarkers, when genetic variants regulating protein levels are included in the model. This current study using plasma biomarker levels as quantitative traits can be critical to identification of novel genes that impact AD and more accurate interpretation of plasma biomarker levels.